{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:25:14Z","timestamp":1692332714732},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Heart failure is a leading cause of hospital admissions and death in the United States and worldwide. In 2016, the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America released a joint focused guideline update for the management of patients with Stage C heart failure with reduced ejection fraction. An additional update released in 2017 reinforces the 2016 update's strong recommendation for substituting angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with an angiotensin receptor-neprilysin inhibitor to reduce morbidity and mortality in selected patients. The 2017 and 2016 updates also support adding a sinoatrial node modulator to further reduce heart rates in patients already maximized on beta-blocker therapy. These innovative therapies can significantly improve patients' quality of life and reduce the healthcare costs associated with managing heart failure.<\/jats:p>","DOI":"10.1097\/01.jaa.0000550282.19722.93","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T19:56:58Z","timestamp":1570564618000},"page":"11-15","source":"Crossref","is-referenced-by-count":1,"title":["No longer failing to treat heart failure"],"prefix":"10.1097","volume":"32","author":[{"given":"Jonathan","family":"Parch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"6","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"issue":"16","key":"R2-20230817","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"R4-20230817","first-page":"e282","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"R5-20230817","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"7228","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bmj.320.7228.167","article-title":"ABC of heart failure. Pathophysiology","volume":"320","author":"Jackson","year":"2000","journal-title":"BMJ"},{"issue":"20","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Peacock","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive servo-ventilation for central sleep apnea in systolic heart failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","article-title":"Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients","volume":"65","author":"Bay\u00e9s-Gen\u00eds","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"R13-20230817","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11897-016-0297-5","article-title":"Neprilysin inhibition as a PARADIGM shift in heart failure therapy","volume":"13","author":"Hsiao","year":"2016","journal-title":"Curr Heart Fail Rep"},{"issue":"8","key":"R15-20230817","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"9230","key":"R16-20230817","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"R17-20230817","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"R18-20230817","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1310\/hpj5011-1025","article-title":"Sacubitril\/valsartan","volume":"50","author":"Cada","year":"2015","journal-title":"Hosp Pharm"},{"issue":"4","key":"R19-20230817","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/2048872615626355","article-title":"Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care","volume":"6","author":"Mair","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9744","key":"R20-20230817","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01720610-201901000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:06:26Z","timestamp":1692320786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201901000-00002"}},"subtitle":["A guideline update review"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000550282.19722.93","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}